S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
MarketBeat Week in Review – 12/4 - 12/8
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Dozens of animals taken from Virginia roadside zoo as part of investigation
Military-themed brewery wants to open in a big Navy town. An ex-SEAL is getting in the way
New CBOE “special perk” helps traders target income every weekend (Ad)
Agriculture gets its day at COP28, but experts see big barriers to cutting emissions
Shohei Ohtani joins big-money club with massive contract with Los Angeles Dodgers
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
Consumer product agency issues warning on small magnetic balls linked to deaths
AP PHOTOS: Moscow hosts a fashion forum with designers from Brazil, China, India and South Africa
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
MarketBeat Week in Review – 12/4 - 12/8
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Dozens of animals taken from Virginia roadside zoo as part of investigation
Military-themed brewery wants to open in a big Navy town. An ex-SEAL is getting in the way
New CBOE “special perk” helps traders target income every weekend (Ad)
Agriculture gets its day at COP28, but experts see big barriers to cutting emissions
Shohei Ohtani joins big-money club with massive contract with Los Angeles Dodgers
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
Consumer product agency issues warning on small magnetic balls linked to deaths
AP PHOTOS: Moscow hosts a fashion forum with designers from Brazil, China, India and South Africa
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
MarketBeat Week in Review – 12/4 - 12/8
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Dozens of animals taken from Virginia roadside zoo as part of investigation
Military-themed brewery wants to open in a big Navy town. An ex-SEAL is getting in the way
New CBOE “special perk” helps traders target income every weekend (Ad)
Agriculture gets its day at COP28, but experts see big barriers to cutting emissions
Shohei Ohtani joins big-money club with massive contract with Los Angeles Dodgers
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
Consumer product agency issues warning on small magnetic balls linked to deaths
AP PHOTOS: Moscow hosts a fashion forum with designers from Brazil, China, India and South Africa
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
MarketBeat Week in Review – 12/4 - 12/8
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Dozens of animals taken from Virginia roadside zoo as part of investigation
Military-themed brewery wants to open in a big Navy town. An ex-SEAL is getting in the way
New CBOE “special perk” helps traders target income every weekend (Ad)
Agriculture gets its day at COP28, but experts see big barriers to cutting emissions
Shohei Ohtani joins big-money club with massive contract with Los Angeles Dodgers
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
Consumer product agency issues warning on small magnetic balls linked to deaths
AP PHOTOS: Moscow hosts a fashion forum with designers from Brazil, China, India and South Africa

Ascendis Pharma A/S Stock Price, News & Analysis (NASDAQ:ASND)

$107.69
-1.11 (-1.02%)
(As of 12/8/2023 ET)
Compare
Today's Range
$106.49
$111.41
50-Day Range
$86.10
$108.80
52-Week Range
$64.33
$127.77
Volume
1.47 million shs
Average Volume
528,744 shs
Market Capitalization
$6.21 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$140.43

Ascendis Pharma A/S MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
30.4% Upside
$140.43 Price Target
Short Interest
Bearish
8.65% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.66mentions of Ascendis Pharma A/S in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($9.85) to ($7.53) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.01 out of 5 stars

Medical Sector

493rd out of 932 stocks

Pharmaceutical Preparations Industry

216th out of 431 stocks


ASND stock logo

About Ascendis Pharma A/S Stock (NASDAQ:ASND)

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company also develops TransCon Growth Hormone for treating pediatric GHD, adult GHD, and turner syndrome; TransCon Parathyroid Hormone for adult patients with hypoparathyroidism; and TransCon C-type natriuretic peptide for achondroplasia. In addition, it is developing TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/? for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

ASND Stock Price History

ASND Stock News Headlines

New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology
Autonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
See More Headlines
Receive ASND Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ascendis Pharma A/S and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/07/2023
Today
12/09/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/15/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ASND
Employees
797
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$140.43
High Stock Price Target
$192.00
Low Stock Price Target
$113.00
Potential Upside/Downside
+30.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
9 Analysts

Profitability

Net Income
$-614,450,000.00
Net Margins
-391.76%
Pretax Margin
-391.15%

Debt

Sales & Book Value

Annual Sales
$53.93 million
Book Value
$4.87 per share

Miscellaneous

Free Float
34,596,000
Market Cap
$6.21 billion
Optionable
Optionable
Beta
0.51
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

  • Mr. Jan Moller Mikkelsen (Age 63)
    President, CEO, Member of Executive Board & Executive Director
  • Mr. Scott T. Smith (Age 49)
    CFO, Executive VP & Member of Executive Board
  • Ms. Lotte Sonderbjerg (Age 62)
    Executive VP, Chief Administrative Officer & Member of the Executive Board
  • Mr. Michael Wolff Jensen L.L.M. (Age 52)
    Executive VP, Chief Legal Officer & Member of the Executive Board
  • Mr. Peter Rasmussen (Age 54)
    VP of Finance & Principal Accounting Officer
  • Mr. Timothy J. Lee
    Senior Director of Investor Relations
  • Mr. Flemming Steen Jensen (Age 62)
    Executive Vice President of Product Supply & Quality - Endocrinology Rare Diseases
  • Dr. Kennett Sprogoe Ph.D. (Age 44)
    Executive Vice President of Research & Product Development
  • Dr. Birgitte Volck M.D. (Age 61)
    Ph.D., Executive VP and Head of Clinical Development & Medical Affairs - Endocrinology Rare Diseases
    Comp: $25.4k
  • Dr. Vibeke Miller Breinholt Ph.D. (Age 56)
    Executive Vice President of Nonclinical Development & Bioanalysis














ASND Stock Analysis - Frequently Asked Questions

Should I buy or sell Ascendis Pharma A/S stock right now?

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ascendis Pharma A/S in the last twelve months. There are currently 3 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ASND shares.
View ASND analyst ratings
or view top-rated stocks.

What is Ascendis Pharma A/S's stock price target for 2024?

9 brokers have issued 1 year target prices for Ascendis Pharma A/S's shares. Their ASND share price targets range from $113.00 to $192.00. On average, they predict the company's stock price to reach $140.43 in the next year. This suggests a possible upside of 30.4% from the stock's current price.
View analysts price targets for ASND
or view top-rated stocks among Wall Street analysts.

How have ASND shares performed in 2023?

Ascendis Pharma A/S's stock was trading at $122.13 at the start of the year. Since then, ASND stock has decreased by 11.8% and is now trading at $107.69.
View the best growth stocks for 2023 here
.

Are investors shorting Ascendis Pharma A/S?

Ascendis Pharma A/S saw a drop in short interest in November. As of November 15th, there was short interest totaling 4,990,000 shares, a drop of 9.8% from the October 31st total of 5,530,000 shares. Based on an average daily volume of 379,600 shares, the days-to-cover ratio is presently 13.1 days.
View Ascendis Pharma A/S's Short Interest
.

When is Ascendis Pharma A/S's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 15th 2024.
View our ASND earnings forecast
.

How were Ascendis Pharma A/S's earnings last quarter?

Ascendis Pharma A/S (NASDAQ:ASND) issued its earnings results on Tuesday, November, 7th. The biotechnology company reported ($3.12) EPS for the quarter, missing analysts' consensus estimates of ($2.63) by $0.49. The biotechnology company earned $52.02 million during the quarter, compared to the consensus estimate of $52.54 million. Ascendis Pharma A/S had a negative trailing twelve-month return on equity of 570.61% and a negative net margin of 391.76%.

What other stocks do shareholders of Ascendis Pharma A/S own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ascendis Pharma A/S investors own include AbbVie (ABBV), Alexion Pharmaceuticals (ALXN), Neurocrine Biosciences (NBIX), ACADIA Pharmaceuticals (ACAD), BioMarin Pharmaceutical (bmrn), Gilead Sciences (GILD), Incyte (INCY), Exelixis (EXEL), GW Pharmaceuticals (GWPH) and NVIDIA (NVDA).

When did Ascendis Pharma A/S IPO?

(ASND) raised $85 million in an initial public offering on Wednesday, January 28th 2015. The company issued 5,000,000 shares at a price of $16.00-$18.00 per share. BofA Merrill Lynch and Leerink Partners acted as the underwriters for the IPO and Wells Fargo Securities was co-manager.

Who are Ascendis Pharma A/S's major shareholders?

Ascendis Pharma A/S's stock is owned by many different retail and institutional investors. Top institutional shareholders include RA Capital Management L.P. (18.59%), Artisan Partners Limited Partnership (10.40%), FMR LLC (8.91%), Westfield Capital Management Co. LP (6.59%), Massachusetts Financial Services Co. MA (2.19%) and TimesSquare Capital Management LLC (1.46%).

How do I buy shares of Ascendis Pharma A/S?

Shares of ASND stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:ASND) was last updated on 12/10/2023 by MarketBeat.com Staff

My Account -